Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035967 | 0.79 | SLC6A4 (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL26720641 | 0.67 | SLC6A4 (0.42) | SLC6A4SLC6A3OPRM1 | |
| SCHEMBL20921539 | 0.66 | SLC6A4 (0.38) | SLC6A4SLC6A3 | |
| SCHEMBL3037887 | 0.64 | SLC6A4 (0.39) | SLC6A4SLC6A3 | |
| SCHEMBL7175250 | 0.63 | SLC6A4 (0.40) | SLC6A4SLC6A3OPRM1 | |
| SCHEMBL6261364 | 0.61 | SLC6A4 (0.33) | SLC6A4SLC6A3OPRM1 | |
| SCHEMBL1492455 | 0.60 | — | — | |
| Trimethylammonium SCHEMBL28741670 | 0.60 | OPRM1 (0.70) | OPRM1 | |
| SCHEMBL7756399 | 0.60 | OPRM1 (0.33) | SLC6A4SLC6A3OPRM1 | |
| SCHEMBL15061781 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-1874721-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006067414-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067414-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC6A4 9/4885SLC6A3 7/4885OPRM1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.